Addimmune™ Launch Party Highlights

Addimmune™ launched in June 2023 with the sole purpose of curing HIV. Building upon the success of the American Gene Technologies® HIV clinical trial, Addimmune is singularly focused on developing and commercializing an effective and lasting cure for HIV using gene and cell therapy. CEO Jeff Galvin announced encouraging results from the Phase 1 clinical trial which spurred the creation of Addimmune. To celebrate, several hundred leaders and stakeholders from Montgomery County and beyond joined our team in commemorating this major milestone. Visit our website: https://www.addimmune.com/ Subscribe to our newsletter: https://www.addimmune.com/in-the-news/ Follow Addimmune on social media: Facebook:   / addimmune   Twitter:   / addimmune   LinkedIn:   / addimmune   Instagram:   / addimmune   Threads: https://www.threads.net/@addimmune Follow Jeff Galvin on social media: Twitter: @jeffreygalvin   / jeffreygalvin   LinkedIn:   / jeff-galvin   Follow AGT on social media: Facebook:   / amerigene   Twitter:   / americangene   LinkedIn:   / american-gene-technologies-international-inc   Instagram:   / americangenetechnologies   Threads: https://www.threads.net/@americangene... Visit AGT’s website: https://www.americangene.com Subscribe to AGT’s newsletter: https://bit.ly/3ughPNR Follow Jeff Galvin on social media: Twitter: @jeffreygalvin   / jeffreygalvin   LinkedIn:   / jeff-galvin